G. Tosetti

Development of a thin-layer scintillation-based dosimeter for surface dose measurement in radiotherapy

G. Tosetti, J.M. Fontbonne, D. Lebhertz, C. Moignier et autres

Abstract Non-melanoma skin cancers (NMSCs) account for nearly 96% of all diagnosed skin cancers worldwide and are often treated surgically. However, when surgery is not feasible, radiotherapy is a valid alternative treatment. In radiotherapy, patient-specific quality assurance (PSQA) relies on dose distribution …

fr, lu (code pays fourni par la source)

Exploratory energy deposition studies in the superconducting dipole magnet of the carbon-ion gantry for the National Center for Oncological Hadrontherapy

G. Tosetti, Alessio Mereghetti, M. G. Pullia

In the context of the HITRI project and EuroSIG international collaboration, a carbon-ion gantry is being designed for possible installation at the National Center for Oncological Hadrontherapy (CNAO), Pavia, Italy. The design is based on superconducting (SC) magnet technology for the dipoles, …

it (code pays fourni par la source)

Predictors of esophago-gastric varices and variceal bleeding in patients receiving atezolizumab/bevacizumab for unresectable hepatocellular carcinoma

Sara Ascari, R. Chen, M. Iavarone, Bernardo Stefanini et autres

it (code pays fourni par la source)

Thrombus generation under flow conditions in patients with cirrhosis and thrombocytopenia: the CirTAS-study

N. Bitto, G. Tosetti, Armando Tripodi, Anna Lecchi et autres

it (code pays fourni par la source)

Incidence and risk factors of esophagogastric varices bleeding in cirrhotic patients with advanced hepatocellular carcinoma treated with lenvatinib

M. Iavarone, E. Alimenti, T. Tada, S. Shimose et autres

Supplementary Material for: Incidence and predictors of esophagogastric varices bleeding in patients with hepatocellular carcinoma in lenvatinib

M. Iavarone, E. Alimenti, Toshifumi Tada, S. Shimose et autres

Introduction: Lenvatinib is indicated for the forefront treatment of advanced hepatocellular carcinoma (aHCC), but its use maybe limited by the risk of esophagogastric varices (EGV) bleeding. This study assessed the prevalence, predictors, and complications of EGV in aHCC patients treated with lenvatinib. …

Supplementary Material for: Incidence and predictors of esophagogastric varices bleeding in patients with hepatocellular carcinoma in lenvatinib

M. Iavarone, E. Alimenti, Toshifumi Tada, S. Shimose et autres

Introduction: Lenvatinib is indicated for the forefront treatment of advanced hepatocellular carcinoma (aHCC), but its use maybe limited by the risk of esophagogastric varices (EGV) bleeding. This study assessed the prevalence, predictors, and complications of EGV in aHCC patients treated with lenvatinib. …

Supplementary Material for: Incidence and predictors of esophagogastric varices bleeding in patients with hepatocellular carcinoma in lenvatinib

M. Iavarone, E. Alimenti, Toshifumi Tada, S. Shimose et autres

Introduction: Lenvatinib is indicated for the forefront treatment of advanced hepatocellular carcinoma (aHCC), but its use maybe limited by the risk of esophagogastric varices (EGV) bleeding. This study assessed the prevalence, predictors, and complications of EGV in aHCC patients treated with lenvatinib. …